Comparative Study of the Mechanism of Action of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity: a Proof of Concept Controlled Trial

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

This is a randomized parallel group clinical trial which will be conducted in three countries (Spain, Canada and Belgium) comparing Botulinum Toxin type A (BTX-A) and Dry Needling (DN) effectiveness for post-stroke spasticity in participants who had a first stroke in the previous 12 months and have plantar flexor spasticity. Participants will be randomly allocated to receive either one session of BTX-A or 12 weekly sessions of DN. Blinded evaluators will assess the effects before, during, and after treatment, and at a 4-week follow-up.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• aged 18-75 years.

• post-stroke spasticity in ankle plantar flexors (Modified Ashworth Scale (MAS) scores of 1-2).

• first stroke.

• 0-12 months evolution.

• no previous BTX-A or DN treatment for spasticity.

• ankle passive range of motion ≥ 20° (approximately) with knee flexion \

⁃ 30°.

• independent ambulation with or without aids.

Locations
Other Locations
Belgium
Universiteit Antwerpen
RECRUITING
Antwerp
Canada
Jewish Rehabilitation Hospital
RECRUITING
Montreal
Spain
Hospital Clínico Universitario Lozano Blesa
NOT_YET_RECRUITING
Zaragoza
Contact Information
Primary
Pablo Herrero Gallego, PhD
pherrero@unizar.es
+34646168248
Backup
Clara Pujol Fuentes, Msc
clara.pujol.fisioterapeuta@gmail.com
+34661075990
Time Frame
Start Date: 2024-09-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 90
Treatments
Active_comparator: Botulinum Toxin type A
The BTX-A group will receive onabotulinumtoxinA (Botox®, Allergan) with mandatory muscles getting 300 units and optional muscles getting up to 100 additional units (maximum dose of 400 units) (14) delivered with a 27-gauge (0.45 mm) beveled needle. Target muscles will be identified by ultrasound imaging or muscle stimulation. Local anesthesia will not be used. Patient positioning will be standardized.
Active_comparator: Dry Needling
For Dry Needling group solid, filiform non-beveled 0.30 mm caliber needles will be used. Target muscles will be identified by ultrasound imaging or muscle stimulation. Local anesthesia will not be used. Patient positioning will be standardized.
Related Therapeutic Areas
Sponsors
Collaborators: Fonds de la Recherche en Santé du Québec, Instituto de Investigación Sanitaria Aragón, McGill University, Instituto de Salud Carlos III, Research Foundation Flanders
Leads: Universiteit Antwerpen

This content was sourced from clinicaltrials.gov